Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02785029
Other study ID # S-2015-1-aa
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date June 2016
Est. completion date July 2023

Study information

Verified date August 2023
Source Heidelberg Engineering GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, single-arm clinical multicenter study intends to measure normal structural parameters of the optic nerve head, the peripapillary retinal nerve fiber layer, and the macula using the Heidelberg Spectralis OCT device. This study is conducted in African-American descent volunteers. The main goal of the study is to provide the range of these structural parameters in normal eyes.


Description:

This prospective, single-arm clinical multicenter study intends to measure normal structural parameters of the optic nerve head, the peripapillary retinal nerve fiber layer, and the macula using the Heidelberg Spectralis OCT device. This study is conducted in African-American descent volunteers. The main goal of the study is to provide the range of these structural parameters in normal eyes. The study will include at least 240 normal volunteers; up to 10 study sites will recruit subjects. Overall an approximately equal age distribution from 18 to 90 years and an approximately equal number of females and males will be enrolled (approximately 40-60% females in each age group). All subjects will undergo Spectralis OCT imaging, biometric and ophthalmoscopic examination, disc photography and visual field testing in one single visit, if possible. Repeated perimetry or Spectralis scans may be performed at a second visit within 30 days of the initial visit. All examinations performed on the subjects are non-significant risk procedures.


Recruitment information / eligibility

Status Terminated
Enrollment 234
Est. completion date July 2023
Est. primary completion date May 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Able and willing to undergo the test procedures, give consent, and to follow instructions. - Signed informed consent - Age =18 to 90. - Healthy eye without prior intraocular surgery (except cataract surgery and Laser in Situ Keratomileusis) and without clinically significant vitreal, retinal or choroidal diseases, clinically significant diabetic retinopathy (subject may have diabetes), or disease of the optic nerve. Small drusen are acceptable in older subjects. - Black or African-American decent (self-reported) - Negative history of glaucoma (not including family history) - Intraocular pressure =21mmHg. - Best corrected visual acuity =20/40. - Refraction between +6 and -6 diopters and astigmatism = 2 diopters. - Axial length = 26.0 mm (by optical biometry) - Normal visual field with Glaucoma Hemifield Test and Mean Deviation within normal limits or not abnormal visual field by judgment of the ophthalmologist / optometrist - Clinically normal appearance of the optic disc, with normal appearing neuroretinal rim with respect to color and shape. The optic disc is examined ophthalmoscopically and by evaluation of stereo photographs. - If both eyes are eligible, both eyes enter the study. Exclusion Criteria: - Vulnerable subjects (as defined in ISO 14155 GCP) with the exception of employees of the site, and, if applicable, students of the respective university. Staff that is listed on the delegation form are excluded from participation. - Subjects unable to read or write - Unreliable visual field. The reliability indices should be used as guide as well as the perimetrist's notes. - Unusable disc stereo photos. - Inability to undergo the tests. - Insufficient quality of Spectralis OCT images (this is not determined until after Spectralis OCT examination, and is an unusual circumstance). Minimum requirements are: - Retina completely included in image frame, - Quality Score = 20 in the stored ART mean images, and - For ONH-R scan: Center position error = 100 µm.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
OCT


Locations

Country Name City State
United States Illinois Eye Institute, Illinois College of Optometry Chicago Illinois
United States St Albans Community Living, Center, Queens Campus Jamaica New York
United States University California San Diego La Jolla California
United States Mid Florida Eye Center Clinic Mount Dora Florida
United States SUNY College of Optometry New York New York
United States Wills Eye Hospital Philadelphia Pennsylvania
United States Assil Eye Institute Santa Monica California
United States Ophthalmic Consultants of Long Island-Valley Stream Valley Stream New York

Sponsors (1)

Lead Sponsor Collaborator
Heidelberg Engineering GmbH

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bruch-Membrane-Opening - Minimum Rim Width (µm) Bruch-Membrane-Opening - Minimum Rim Width (µm) Baseline
Primary Bruch-Membrane-Opening - Minimum Rim Area (µm^2) Bruch-Membrane-Opening - Minimum Rim Area (µm^2) Baseline
Primary Peripapillary Retinal Nerve Fibre Layer Thickness (µm) Peripapillary Retinal Nerve Fibre Layer Thickness (µm) Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3